Format

Send to

Choose Destination
Am J Kidney Dis. 2013 Mar;61(3):430-9. doi: 10.1053/j.ajkd.2012.10.016. Epub 2012 Dec 8.

Performance of urinary liver-type fatty acid-binding protein in acute kidney injury: a meta-analysis.

Author information

1
Department of Medicine, Division of Nephrology, Kidney and Dialysis Research Laboratory, St. Elizabeth's Medical Center, Boston, MA 02135, USA.

Abstract

BACKGROUND:

Urinary liver-type fatty acid-binding protein (L-FABP) is a proximal tubular injury candidate biomarker for early detection of acute kidney injury (AKI), with variable performance characteristics depending on clinical settings.

STUDY DESIGN:

Meta-analysis of diagnostic test studies assessing the performance of urinary L-FABP in AKI.

SETTING & POPULATION:

Literature search in MEDLINE, EMBASE, Scopus, Google Scholar, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov using search terms "liver-type fatty acid-binding protein" and "L-FABP."

SELECTION CRITERIA FOR STUDIES:

Studies of humans investigating the performance characteristics of urinary L-FABP for the early diagnosis of AKI and AKI-related outcomes, including dialysis requirement and mortality.

PREDICTOR:

Urinary L-FABP.

OUTCOMES:

Diagnosis of AKI, dialysis requirement, and in-hospital death.

RESULTS:

15 prospective cohort and 2 case-control studies were identified. Only 7 cohort studies could be meta-analyzed. The estimated sensitivity of urinary L-FABP level for the diagnosis of AKI was 74.5% (95% CI, 60.4%-84.8%), and specificity was 77.6% (95% CI, 61.5%-88.2%). The estimated sensitivity of urinary L-FABP level for predicting dialysis requirement was 69.1% (95% CI, 34.6%-90.5%), and specificity was 42.7% (95% CI, 3.1%-94.5%); for in-hospital mortality, sensitivity and specificity were 93.2% (95% CI, 66.2%-99.0%) and 78.8% (95% CI, 27.0%-97.4%), respectively.

LIMITATIONS:

Paucity and low quality of studies, different clinical settings, and variable definitions of AKI.

CONCLUSIONS:

Although urinary L-FABP may be a promising biomarker for early detection of AKI and prediction of dialysis requirement and in-hospital mortality, its potential value needs to be validated in large studies and across a broader spectrum of clinical settings.

PMID:
23228945
PMCID:
PMC3578035
DOI:
10.1053/j.ajkd.2012.10.016
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center